Disclosed herein are new 3-Amino Quinoxaline-6-Carboxylic Acid compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting purine-analog sensitive kinase (PASK) activity in a human or animal subject, also provided for is the treatment of diseases such as diabetes mellitus. Compounds of the disclosure include: (R)-2-(4-Fluorophenyl)-3-(2-(trifluoromethyl)pyrrolidin-1-yl)quinoxaline-6-carboxylic acid, (R)-2-(Benzo[d][1,3]dioxol-5-yl)-3-(2-methylpyrrolidin-1-yl)quinoxaline-6-carboxylic acid, (S)-2-(1H-Indol-5-yl)-3-(3-methylmorpholino)quinoxaline-6-carboxylic acid, 3-(Azepan-1-yl)-2-(1H-indazol-5-yl)quinoxaline-6-carboxylic acid, and (S)-2-(4-Fluorophenyl)-3-(3-methylmorpholino)quinoxaline-6-carboxylic acid.
